Anti-IFITM3 Antibody, clone 1K3 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Interferon-induced transmembrane protein 3 (UniProt: Q01628; also known as Dispanin subfamily A member 2b (DSPA2b), Interferon-inducible protein 1-8U) is encoded by the IFITM3 gene (Gene ID: 10410) in human. The interferon-induced transmembrane protein 3 (IFITM3) is a member of a conserved small transmembrane protein family implicated in cell adhesion, stem cell migration, leucocyte apoptosis, and antiviral defense mechanisms as part of innate immunity. It is localized predominantly to endosomal and lysosomal compartments, where it acts to inhibit viral entry into host cells by preventing viral fusion with cellular membranes. This function is modulated by post-translational modifications, including phosphorylation and ubiquitination, which regulate its antiviral activity. IFITM3 plays a critical role in subcellular viral trafficking by binding incoming virus particles and shuttling them to endosomes for degradation, effectively halting viral propagation. Recent studies have highlighted the broader physiological roles of IFITM3, including its involvement in immune regulation, cancer progression, and neurodegenerative diseases such as Alzheimer′s disease. IFITM3 interacts with -secretase, modulating amyloid precursor protein (APP) processing and promoting amyloid-beta peptide production, thereby potentially contributing to Alzheimer′s pathogenesis. The expression of IFITM3 is highly regulated by type I, II, and III interferons, and its upregulation is often associated with inflammation, aging, and infection. Genetic variations in the IFITM3 gene, such as the SNP rs12252, have been linked to differential susceptibility to viral infections, including influenza and COVID-19, as well as tumorigenesis. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

KLH-conjugated linear peptide corresponding to 13 amino acids from the N-terminal region of human IFITM3.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysates.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected IFITM3 in HeLa cell lysates.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected IFITM3 in MCF7 cell lysates.

Affinity Binding Assay: A representative lot of this antibody bound with IFITM3 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected IFITM3 in human spleen tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1K3 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects IFITM3. It targets an epitope within 13 amino acids from the N-terminal region.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.